NSD2 is associated with tumor aggressiveness or prognosis in most types of cancers, including prostate cancer and multiple myeloma and is overexpressed in at least 15 different cancers [9,10,17,18,20,21,25,29-33]. The gene discussed is NSD2; the disease is plasma cell myeloma.